Broderick Brian C Trims Position in Becton, Dickinson and Company (NYSE:BDX)

by · The Cerbat Gem

Broderick Brian C trimmed its position in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 11.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,583 shares of the medical instruments supplier’s stock after selling 210 shares during the period. Broderick Brian C’s holdings in Becton, Dickinson and Company were worth $359,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Brighton Jones LLC lifted its stake in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the period. E. Ohman J or Asset Management AB raised its position in Becton, Dickinson and Company by 13.4% in the fourth quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier’s stock worth $39,951,000 after acquiring an additional 20,859 shares during the period. Arete Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth $767,000. Busey Bank grew its position in shares of Becton, Dickinson and Company by 3.8% during the 4th quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier’s stock valued at $15,031,000 after acquiring an additional 2,399 shares during the period. Finally, Centre Asset Management LLC bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at $8,382,000. 86.97% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Bertram L. Scott sold 700 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total value of $159,593.00. Following the sale, the director now directly owns 36,033 shares of the company’s stock, valued at approximately $8,215,163.67. The trade was a 1.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Richard Byrd sold 1,940 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $224.91, for a total value of $436,325.40. Following the transaction, the executive vice president now directly owns 7,411 shares of the company’s stock, valued at approximately $1,666,808.01. The trade was a 20.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 4,984 shares of company stock worth $1,147,865 in the last 90 days. 0.36% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

BDX has been the topic of several analyst reports. Piper Sandler lifted their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. Barclays lifted their price objective on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $278.29.

Read Our Latest Stock Report on BDX

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $221.59 on Friday. The stock has a 50-day moving average price of $230.78 and a 200 day moving average price of $231.51. The stock has a market capitalization of $63.63 billion, a P/E ratio of 36.81, a P/E/G ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its board has approved a stock buyback plan on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 31st. Shareholders of record on Monday, March 10th were paid a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 1.88%. The ex-dividend date of this dividend was Monday, March 10th. Becton, Dickinson and Company’s payout ratio is currently 69.10%.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Articles

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).